ArticleBlood advances2026
Short- and long-term effects of transfusion in β-thalassemia: a longitudinal study of transfusion efficiency factors.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Acute pain transfusion reaction in a patient with thalassemia: In-depth characterization of short- and long-term phenotypes.Transfusion · 2026Article
- Red blood cell membrane proteome as a reporter of disease severity, transfusion impact and genetic background in transfusion-dependent β-thalassaemia.British journal of haematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractThe complex interplay between donor and recipient factors likely influences transfusion outcomes in transfusion-dependent thalassemia (TDT). We investigated physiological responses to transfusion shortly after it and 1 week later, focusing on hemoglobin (Hb) increment (ΔHb) and its determinants, using longitudinal data from 36 patients with TDT and 58 red blood cell (RBC) units. Immediate anemia correction after transfusion was associated with decreases in platelets and nucleated RBCs, increases in ADAMTS13 antigen and plasma amino acid levels, and temporary rises in hemolysis and phthalates. One week after transfusion, at the peak of erythroid suppression, plasma antioxidants and mechanical hemolysis decreased, whereas proteasome activity at the RBC membrane increased. Leukocyte levels declined, markers of thrombotic risk and endothelium dysfunction improved, and hepcidin as well as plasma glutamine and deoxyadenosine, increased. In addition to female sex and anemia, ΔHb was influenced by recipient baseline monocyte levels, hypercoagulability, and plasma metabolites, such as methionine, adenosine, acyl-carnitines, and bile acids. Donor RBC unit factors, including residual platelet levels, RBC proteasome activity, arginine metabolism, and catecholamine content also had significant correlations. Notably, the baseline neutrophil-to-lymphocyte ratio strongly affected ΔHb soon after transfusion, after adjusting for confounders. At the 1-week mark, ΔHb correlated with storability markers, such as oxidative hemolysis and phthalates, which, to our knowledge, is a first-ever described connection. Importantly, the percentage of phosphatidylserine-exposing donor RBCs and the uric acid-dependent antioxidant capacity of the RBC units significantly influenced ΔHb at the 1-week time point. These findings enhance our understanding of transfusion dynamics, paving the way for more personalized and effective care strategies in TDT management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.